echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Efficacy of rituximab targeted therapy in patients with active moderate to severe Graves ophthalmopathy

    JCEM: Efficacy of rituximab targeted therapy in patients with active moderate to severe Graves ophthalmopathy

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     Current studies have shown that rituximab (RTX) is effective for active Graves' ophthalmopathy (GO)


    Rituximab (RTX) is effective for active Graves ophthalmopathy (GO)

     Methods: To compare the effects of RTX and intravenous methylprednisolone (ivMP) in the treatment of patients with active moderate to severe Graves ophthalmopathy (GO)


    Methods: To compare the effects of RTX and intravenous methylprednisolone (ivMP) in the treatment of patients with active moderate to severe Graves ophthalmopathy (GO)


     Results: The clinical activity scores of the two groups of patients decreased, but decreased more after 16 weeks, 20 weeks and 24 weeks of RTX (P<0.


    Figure 1 The primary endpoint of the analysis study


    Figure 2 Changes in serum TRAbs activity of GO patients after intravenous injection of MP or RTX from baseline to 76-week follow-up


    Conclusion: The results of this trial confirmed the preliminary report that compared with ivMP, even with lower doses of RTX, RTX is more effective in the treatment of active moderate to severe GO


    The results of this trial confirmed the preliminary report that, compared with ivMP, even with lower doses of RTX, RTX is more effective in the treatment of active moderate to severe GO


    Original source:

    Salvi M, Vannucchi G, Currò N, et al, Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study .


    Salvi M, Vannucchi G, Currò N, et al, Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study .
    Efficacy of B-cell targeted therapy with rituximab in patients with active Graves 'to Severe.
    Moderate' orbitopathy: A randomized Controlled Study J Clin Endocrinol Metab, 2015 on Feb; 100 (2)

    in this message

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.